目的 探討積雪苷片聯(lián)合曲尼司特治療瘢痕疙瘩的臨床療效。方法 選取2015年1月—2017年1月在河南省職工醫(yī)院診治的瘢痕疙瘩患者66例，隨機(jī)分為對(duì)照組（33例）和治療組（33例）。對(duì)照組口服曲尼司特膠囊，0.1 g/次，3次/d。治療組在對(duì)照組的基礎(chǔ)上口服積雪苷片，0.2 g/次，2次/d。兩組均經(jīng)過(guò)8周治療。觀察兩組患者臨床療效，比較治療前后兩組患者溫哥華瘢痕量表（VSS）、視覺模擬評(píng)分（VAS）、焦慮自評(píng)量表（SAS）、抑郁自評(píng)量表（SDS）和QLQ-C30評(píng)分及瘢痕厚度和瘢痕面積。結(jié)果 治療后，對(duì)照組和治療組臨床總有效率分別為72.73%、93.94%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組VSS評(píng)分、VAS評(píng)分、SAS評(píng)分和SDS評(píng)分均顯著降低（P < 0.05）；且治療組上述評(píng)分均低于對(duì)照組（P < 0.05）。治療后，兩組瘢痕厚度和瘢痕面積均明顯減小（P < 0.05）；且治療組比對(duì)照組減小更顯著（P < 0.05）。治療后，兩組QLQ-C30功能領(lǐng)域評(píng)分均明顯增高（P < 0.05）；且治療組比對(duì)照組增高更顯著（P < 0.05）。結(jié)論 積雪苷片聯(lián)合曲尼司特治療瘢痕疙瘩有利于改善患者臨床癥狀，提高患者生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the clinical efficacy of Jixuegan Tablets combined with tranilast in treatment of keloid. Methods Patients (66 cases) with keloid in Henan Staff Hospital from January 2015 to January 2017 were randomly divided into control (33 cases) and treatment (33 cases) groups. Patients in the control group were po administered with Tranilast Capsules, 0.1 g/time, three times daily. Patients in the treatment group were po administered with Jixuegan Tablets on the basis of the control group, 0.2 g/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the VSS, VAS, SAS, SDS and QLQ-C30 scores, scar thickness and scar area in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 72.73% and 93.94%, respectively, and there were differences between two groups (P < 0.05). After treatment, the VSS, VAS, SAS and SDS scores in two groups were significantly decreased (P < 0.05), and the scores in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the scar thickness and scar area in two groups was significantly reduced (P < 0.05), and the scar thickness and scar area in the treatment group were significantly smaller than that in the control group (P < 0.05). After treatment, the QLQ-C30 scores in two groups were significantly increased (P < 0.05), and the QLQ-C30 scores in the treatment group were significantly higher than those in the control group (P < 0.05). Conclusion Jixuegan Tablets combined with tranilast in treatment of keloid can improve the clinical symptoms and the quality of life, which has a certain clinical application value.